Avalon GloboCare Announces Renewed FDA's Establishment Registration For KeoAir Device By Qi Diagnostics

Avalon GloboCare Corp. ("Avalon" or the "Company") (NASDAQ:ALBT), a diversified company focused on the development of precision diagnostic consumer products and generative AI publishing and software, today announced the renewal of the U.S. Food and Drug Administration (FDA) establishment registration for the KetoAir™ device by Qi Diagnostics Limited, a nanosensor-based diagnostic technologies company. Avalon markets and distributes the KetoAir™ device, a handheld breathalyzer designed for ketogenic health management which is registered with the U.S. Food and Drug Administration under registration number 3026284320.

KetoAir™ is a handheld breathalyzer designed for ketogenic health management and is registered with the U.S. Food and Drug Administration under registration number 3026284320. The device measures breath acetone concentration (BrAce), a key biomarker associated with fat metabolism and nutritional ketosis. Leveraging advanced nano-sensor technology, KetoAir™ provides users with real-time, non-invasive insights into metabolic state through breath analysis. The device is intended for individuals pursuing ketogenic diets for weight management, athletic performance, and therapeutic or lifestyle-based ketogenic programs. KetoAir™ is compatible with both iOS and Android smartphones, with companion applications available through the Apple App Store and Google Play Store.